ArticleCardio-oncology (London, England)2026
Association between polygenic risk scores and cardiovascular events in prostate cancer patients receiving androgen deprivation therapy in Han Chinese.
Article in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionCardiovascular disease (CVD) remains one of the leading non-cancer causes of mortality in prostate cancer patients, with previous studies indicating that androgen deprivation therapy (ADT) may increase cardiovascular risk. In this study, we aimed to predict cardiovascular events by incorporating polygenic risk scores (PRS).
methodsData were collected from 24,778 men, including 903 prostate cancer patients at Taichung Veterans General Hospital. Genotyping was performed using the Affymetrix Genome-Wide TWB 2.0 SNP Array. Four PRSs (PGS000337, PGS002262, PGS002725, and PGS003727) associated with coronary artery disease were utilized for analysis. Patients were stratified into quartiles based on their risk levels. Cox proportional hazards models were applied to assess the association between PRSs and the incidence of cardiovascular disease, adjusting for age, androgen deprivation therapy use, and comorbidities.
resultsPGS003727 demonstrated the highest predictive performance, with an area under curve (AUC) of 0.5550. Among ADT-treated patients, those in the highest PRS quartile (Q4) of PGS003727 had a significantly higher risk of CVD compared to those in the lowest quartile (Q1) (HR = 1.892, p = 0.0056). However, this Q4-to-Q1 risk difference was not significant in non-ADT patients (HR = 1.244, p = 0.3951). Kaplan-Meier analysis revealed significant risk variation across Q1 to Q4 in the ADT-treated group (p = 0.028) but not in the non-ADT group. Among Q4 prostate cancer patients, ADT treatment significantly increased CVD risk compared to non-ADT treatment (HR = 1.625, p = 0.0428). Kaplan-Meier analysis further confirmed that ADT treatment was associated with a higher cumulative incidence of CVD in Q4 prostate cancer patients (p = 0.033).
conclusionThis hospital-based cohort study demonstrated that the PRS effectively predicted CVD risk in prostate cancer patients receiving ADT. Integrating this model into clinical practice could enable more precise cardiovascular risk assessment to aid treatment decisions and improving disease prevention strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.